Ribociclib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted ribociclib, while CIPM (Spain) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in c…”, while PBAC (Australia) recorded not recommended for “Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer”.
HAS (France) has been harder on ribociclib than on its own caseload: it refused 3 of 9 decisive submissions here (33%), against a base rate of 11% across everything it has assessed.
Assessment has run over 8.9 years, from 2017 at PBAC (Australia) to 16 Jun 2026 at PHARMAC (New Zealand).
AOTMIT (Poland) changed its position: not recommended on 21 Nov 2018, restricted by 21 May 2025, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for ribociclib.
The file is active: 18 of 50 records date from 2023 or later.
The programme is broad: 11 distinct indication wordings are recorded for ribociclib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 50 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess ribociclib, in 2017; CIPM (Spain) did not open a file until 24 Sep 2025 — an unusually long tail of 8.2 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 9 years in total.
12 of the 14 agencies here assessed ribociclib more than once, HAS (France) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
ribociclib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for ribociclib reads 27 recommended, 8 not recommended, 8 restricted and 3 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 25 Mar 2026 | Indicaciones terapéuticas autorizadas: Cáncer de mama precoz Kisqali en combinación con un inhibidor de la aromatasa est… | not financed by the SNS · art. 92 d | source |
| AIFA (Italy) | 6 Mar 2026 | Kisqali in associazione a un inibitore dell’aromatasi è indicato per il trattamento adiuvante di pazienti con cancro del… | fully innovative status not granted · reimbursed class H | source |
| HAS (France) | 28 Jan 2026 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| DMC (Denmark) | 30 Sep 2025 | I komb. m. en aromatasehæmmer til adjuverende behandling af patienter med hormonreceptor (HR)-positiv, human epidermal v… | Delvist anbefalet | source |
| SMC (Scotland) | 11 Nov 2019 | For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in c… | accepted (restricted) | source |
45 further decisions for ribociclib, across 14 agencies, are not shown here. They include the most recent record on file, 16 Jun 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 29 further source documents.
Related molecules
- neratinib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 50 decisions for ribociclib from 14 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.